Cyrielle Caussy and the Surfers explore final thoughts on identifying NAFLD/NASH patients earlier on in endocrinology settings and the role of allied health professionals in making this possible. Finally, each panelist is asked what they would do if they had a magic wand to touch one thing in their hospital to make a change.
Cyrielle Caussy and the Surfers explore the strength of simple tools that closely link consequence to physicians and push for the identification and risk stratification of respective patient populations. This session also entertains with a fascinating anecdote on the famous composer, Beethoven, and his liver health.
Cyrielle Caussy joins the Surfers to talk about how patients can be motivated by biofeedback to improve both liver health and overall condition. Following, the group discusses how specific phenotypes in chronic kidney patients can be targeted for high risk of NAFLD/NASH.
In continuing conversation around clinical care pathways and the complex of metabolic diseases, SurfingNASH explores the key relationship and interplay between endocrinology and hepatology. This conversation features Cyrielle Caussy alongside Surfers Jörn Schattenberg, Louise Campbell and Roger Green discussing why endocrinology clinics are a critical setting for early identification of patients with NAFLD and NASH.
In continuing conversation around clinical care pathways and the complex of metabolic diseases, SurfingNASH explores the key relationship and interplay between endocrinology and hepatology. Jörn Schattenberg, Louise Campbell and Roger Green are joined by Cyrielle Caussy to discuss interprofessional collaboration, education and awareness on Fatty Liver disease and early identification of at-risk populations.
As part of ongoing dialogue around clinical care pathways and the complex of metabolic diseases, SurfingNASH dedicates a session to focus on the key relationship and interplay between endocrinology and hepatology. Jörn Schattenberg, Louise Campbell and Roger Green are joined by Cyrielle Caussy to discuss interprofessional collaboration and education for early identification of at-risk populations.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group dives into the tremendous progress being made in liver science and ultimately building a roadmap to therapy.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group shares recollections of their introductions to the podcast as we play throwback clips to their debut appearances.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation, Stephen shares his latest work and interests before the group listens and reacts to a clip of the original introduction featured on earlier episodes.
As part of a Surfing NASH 3rd Anniversary Special, Louise Campbell and Roger Green interview CEO and Co-Founder of Inventiva Pharma, Frédéric Cren, to explore the trajectory of NASH therapeutics and Inventiva’s lead product candidate, lanifibranor.
